INCREASED IRON-RELATED MRI CONTRAST IN THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE

被引:268
|
作者
GORELL, JM
ORDIDGE, RJ
BROWN, GG
DENIAU, JC
BUDERER, NM
HELPERN, JA
机构
[1] HENRY FORD HOSP,DEPT PSYCHIAT,DETROIT,MI 48202
[2] HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202
[3] HLTH SCI CTR,DETROIT,MI 48202
[4] OAKLAND UNIV,DEPT PHYS,ROCHESTER,MI
关键词
D O I
10.1212/WNL.45.6.1138
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Elevated iron levels in the substantia nigra (SN) of the brain in Parkinson's disease (PD) may mediate lipid peroxidative reactions, promoting SN neuronal death. To assess SN iron accumulation in living PD patients and its relation to motor performance, we measured, in 13 nondemented PD patients and 10 normal control subjects, simple reaction time (SRT) and simple movement time (SMT), followed by head MRI in a 3-tesla system, We measured T-2 and T-2* in the right and left SN of all subjects and calculated R(2)', the relaxation rate due to local magnetic field inhomogeneities, from these values. Asymmetries of 1/T-2 (R(2)), 1/T-2* (R(2)*), or R(2)' versus asymmetries of SRT and SMT were assessed in eight PD subjects who had not taken anti-PD medication(s) for 12 hours. The average of right and left SN values for R(2) was lower, and R(2)* and R(2)' were higher, in PD patients than in controls (R(2), p = 0.046; R(2)*, p = 0.001; R(2)', p < 0.001). R(2)' best predicted group differences. The asymmetry of SRT performance was highly correlated with asymmetries of SN R(2)* (0.91; p = 0.001) and R(2)' (0.72; p = 0.03). These results strongly suggest that the increases in iron levels seen postmortem in the SN in PD are reflected in increased iron-related MRI contrast at 3 tesla in living PD patients. Correlations with motor performance in PD suggest that the clinical severity of PD may be related to SN iron accumulation.
引用
收藏
页码:1138 / 1143
页数:6
相关论文
共 50 条
  • [2] IRON HISTOCHEMISTRY OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    MORRIS, CM
    EDWARDSON, JA
    NEURODEGENERATION, 1994, 3 (04): : 277 - 282
  • [3] COLLOID INCLUSIONS OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    PAPPOLLA, MA
    DUDLEY, AW
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 86 (03) : 399 - 400
  • [4] THE ENIGMA OF NEUROMELANIN IN PARKINSONS-DISEASE SUBSTANTIA-NIGRA
    YOUDIM, MBH
    BENSHACHAR, D
    RIEDERER, P
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1994, (43): : 113 - 122
  • [5] COMPLEX-I, IRON, AND FERRITIN IN PARKINSONS-DISEASE SUBSTANTIA-NIGRA
    MANN, VM
    COOPER, JM
    DANIEL, SE
    SRAI, K
    JENNER, P
    MARSDEN, CD
    SCHAPIRA, AHV
    ANNALS OF NEUROLOGY, 1994, 36 (06) : 876 - 881
  • [6] INCREASED IRON IN THE NEUROMELANIN-CONTAINING NEURONS IN THE SUBSTANTIA-NIGRA ZONA COMPACTA IN PARKINSONS-DISEASE
    CANDY, JM
    OAKLEY, AE
    MORRIS, CM
    LOVE, G
    PERROTT, H
    EDWARDSON, JA
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 : P71 - P71
  • [7] GLUTAMATE RECEPTORS IN THE SUBSTANTIA-NIGRA OF PARKINSONS-DISEASE BRAINS
    DIFAZIO, MC
    HOLLINGSWORTH, Z
    YOUNG, AB
    PENNEY, JB
    NEUROLOGY, 1992, 42 (02) : 402 - 406
  • [8] AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY
    FEARNLEY, JM
    LEES, AJ
    BRAIN, 1991, 114 : 2283 - 2301
  • [9] IS THE VULNERABILITY OF NEURONS IN THE SUBSTANTIA-NIGRA OF PATIENTS WITH PARKINSONS-DISEASE RELATED TO THEIR NEUROMELANIN CONTENT
    KASTNER, A
    HIRSCH, EC
    LEJEUNE, O
    JAVOYAGID, F
    RASCOL, O
    AGID, Y
    JOURNAL OF NEUROCHEMISTRY, 1992, 59 (03) : 1080 - 1089
  • [10] NEURONAL HYPERTROPHY IN THE PARS RETICULATA OF THE SUBSTANTIA-NIGRA IN PARKINSONS-DISEASE
    NEAL, JW
    PEARSON, RCA
    COLE, G
    POWELL, TPS
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1991, 17 (03) : 203 - 206